Emerging treatments

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Armoiry X et al. Pharmacoeconomics. 2018 Sep. doi: 10.1007/s40273-018-0644-3. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Sep. doi: 10.1007/s00520-018-4165-6. Surgical thyroparathyroidectomy…

Diagnostic techniques and prognostic indicators

The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Jiang Yet al. Oncol Lett. 2018 Sep. doi: 10.3892/ol.2018.9128. [Epub 2018 Jul 11] Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Stolzenburg A et al. Eur J Nucl Med Mol Imaging. 2018 Sep. doi: 10.1007/s00259-018-3997-0. Determining treatment intensity…

Current treatments

Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.] Proteasome inhibitors for multiple myeloma. Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.…

Biology and Genetics

miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27] Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544.…